Arcadia Biosciences
RKDA
13 hedge funds and large institutions have $538K invested in Arcadia Biosciences in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
11.51% less ownership
Funds ownership: 26.11% → 14.6% (-12%)
13% less funds holding
Funds holding: 15 → 13 (-2)
56% less capital invested
Capital invested by funds: $1.21M → $538K (-$671K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$348K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$15.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.6K |
| 4 |
VF
VitalStone Financial
Shavano Park,
Texas
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$616K |
| 2 |
Millennium Management
New York
|
-$76K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$3.05K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$60 |
| 5 |
Morgan Stanley
New York
|
-$27 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $459K | +$348K | +65,339 | +124% |
|
2
State Street
Boston,
Massachusetts
| $47.1K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $19.4K | +$9.6K | +1,801 | +56% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $11.4K | +$15.6K | +2,930 | +146,500% |
|
|
5
Morgan Stanley
New York
| $826 | -$27 | -5 | -2% |
|
6
Group One Trading
Chicago,
Illinois
| $404 | – | – | – |
|
7
BlackRock
New York
| $147 | – | – | – |
|
|
8
Wells Fargo
San Francisco,
California
| $23 | -$3.05K | -573 | -99% |
|
9
US Bancorp
Minneapolis,
Minnesota
| $19 | – | – | – |
|
|
OLVIG
10
Oliver Lagore Vanvalin Investment Group
Flint,
Michigan
| $16 | – | – | – |
|
|
HI
11
Harbour Investments
Madison,
Wisconsin
| $4 | – | – | – |
|
|
AC
12
Armistice Capital
New York
| – | -$616K | -82,500 | Closed |
|
|
13
Millennium Management
New York
| – | -$76K | -10,199 | Closed |
|
|
14
Fidelity Investments
Boston,
Massachusetts
| – | -$60 | -8 | Closed |
|
|
VF
15
VitalStone Financial
Shavano Park,
Texas
| – | +$5 | +1 | New |
|
RKDA Hedge Fund Activity: Q2 2023 in Review
13 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q2 2023, worth a combined $538K — down 56% from $1.21M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RKDA and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, adding an estimated $348K. The largest seller was Armistice Capital, exiting entirely with an estimated $616K sold.
- 13 institutional investors held Arcadia Biosciences (RKDA) as of Q2 2023, down from 15 in Q1 2023.
- Funds reported $538K of Arcadia Biosciences stock for Q2 2023, down 56% quarter-over-quarter.
- 1 fund opened new Arcadia Biosciences positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest Arcadia Biosciences buyer in Q2 2023 was Sabby Management, an estimated $348K added.
- The largest Arcadia Biosciences seller in Q2 2023 was Armistice Capital, an estimated $616K sold.
Based on aggregated 13F filings for Q2 2023.